190 related articles for article (PubMed ID: 28782704)
21. High Gastrointestinal Colonization Rate with Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae in Hospitalized Patients: Emergence of Carbapenemase-Producing K. pneumoniae in Ethiopia.
Desta K; Woldeamanuel Y; Azazh A; Mohammod H; Desalegn D; Shimelis D; Gulilat D; Lamisso B; Makonnen E; Worku A; Mannerqvist K; Struwe J; Aspevall O; Aklillu E
PLoS One; 2016; 11(8):e0161685. PubMed ID: 27574974
[TBL] [Abstract][Full Text] [Related]
22. Risk factors for treatment failure in patients receiving β-lactam/β-lactamase inhibitor combinations for Enterobacteriaceae bloodstream infection: A retrospective, single-centre, cohort study.
Giannella M; Pascale R; Ferraro G; Toschi A; Pancaldi L; Furii F; Bartoletti M; Tedeschi S; Ambretti S; Lewis RE; Viale P
Int J Antimicrob Agents; 2019 May; 53(5):574-581. PubMed ID: 30639527
[TBL] [Abstract][Full Text] [Related]
23. Which proportion of extended-spectrum beta-lactamase producing strains could be treated by non-carbapenem beta-lactams?
Canoui E; Tankovic J; Bige N; Alves M; Offenstadt G
Med Mal Infect; 2014 May; 44(5):235-7. PubMed ID: 24780641
[No Abstract] [Full Text] [Related]
24. Predictors of mortality in patients with bloodstream infections caused by extended-spectrum-beta-lactamase-producing Enterobacteriaceae: importance of inadequate initial antimicrobial treatment.
Tumbarello M; Sanguinetti M; Montuori E; Trecarichi EM; Posteraro B; Fiori B; Citton R; D'Inzeo T; Fadda G; Cauda R; Spanu T
Antimicrob Agents Chemother; 2007 Jun; 51(6):1987-94. PubMed ID: 17387156
[TBL] [Abstract][Full Text] [Related]
25. Risk factors for colonization by carbapenemase-producing enterobacteria at admission to a Surgical ICU: A retrospective study.
Maseda E; Salgado P; Anillo V; Ruiz-Carrascoso G; Gómez-Gil R; Martín-Funke C; Gimenez MJ; Granizo JJ; Aguilar L; Gilsanz F
Enferm Infecc Microbiol Clin; 2017; 35(6):333-337. PubMed ID: 27016135
[TBL] [Abstract][Full Text] [Related]
26. Determining a clinical framework for use of cefepime and β-lactam/β-lactamase inhibitors in the treatment of infections caused by extended-spectrum-β-lactamase-producing Enterobacteriaceae.
Nguyen HM; Shier KL; Graber CJ
J Antimicrob Chemother; 2014 Apr; 69(4):871-80. PubMed ID: 24265230
[TBL] [Abstract][Full Text] [Related]
27. [Empirical therapy of bloodstream infections caused by extended-spectrum β-lactamase-producing Enterobacteriaceae].
Tang CQ; Li JQ; Xia ZF; Wang H; Lü KY; Xiao SC; Deng AM; Huang Y
Zhonghua Yi Xue Za Zhi; 2016 Jul; 96(26):2076-80. PubMed ID: 27468620
[TBL] [Abstract][Full Text] [Related]
28. Comparison of the relative efficacy of β-lactam/β-lactamase inhibitors and carbapenems in the treatment of complicated urinary tract infections caused by ceftriaxone-non-susceptible Enterobacterales: a multicentre retrospective observational cohort study.
Chen L; Hua J; Hong SJ; Yuan CY; Jing RC; Luo XY; Xue HW; Yue Y; He XP
J Antimicrob Chemother; 2023 Mar; 78(3):710-718. PubMed ID: 36691860
[TBL] [Abstract][Full Text] [Related]
29. Colonization with extended-spectrum beta-lactamase-producing and carbapenemase-producing Enterobacteriaceae in international travelers returning to Germany.
Lübbert C; Straube L; Stein C; Makarewicz O; Schubert S; Mössner J; Pletz MW; Rodloff AC
Int J Med Microbiol; 2015 Jan; 305(1):148-56. PubMed ID: 25547265
[TBL] [Abstract][Full Text] [Related]
30. Prevalence and risk factors of infections caused by extended-spectrum β-lactamase (ESBL)-producing Enterobacteriaceae.
Nakai H; Hagihara M; Kato H; Hirai J; Nishiyama N; Koizumi Y; Sakanashi D; Suematsu H; Yamagishi Y; Mikamo H
J Infect Chemother; 2016 May; 22(5):319-26. PubMed ID: 26968486
[TBL] [Abstract][Full Text] [Related]
31. Extended spectrum β-lactamase producing enterobacteriaceae: carbapenem sparing options.
Aslan AT; Akova M
Expert Rev Anti Infect Ther; 2019 Dec; 17(12):969-981. PubMed ID: 31722185
[No Abstract] [Full Text] [Related]
32. Risk factors for bloodstream infection caused by extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae: A focus on antimicrobials including cefepime.
Chopra T; Marchaim D; Johnson PC; Chalana IK; Tamam Z; Mohammed M; Alkatib S; Tansek R; Chaudhry K; Zhao JJ; Pogue JM; Kaye KS
Am J Infect Control; 2015 Jul; 43(7):719-23. PubMed ID: 25934068
[TBL] [Abstract][Full Text] [Related]
33. Empiric Therapy With Carbapenem-Sparing Regimens for Bloodstream Infections due to Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae: Results From the INCREMENT Cohort.
Palacios-Baena ZR; Gutiérrez-Gutiérrez B; Calbo E; Almirante B; Viale P; Oliver A; Pintado V; Gasch O; Martínez-Martínez L; Pitout J; Akova M; Peña C; Molina Gil-Bermejo J; Hernández A; Venditti M; Prim N; Bou G; Tacconelli E; Tumbarello M; Hamprecht A; Giamarellou H; Almela M; Pérez F; Schwaber MJ; Bermejo J; Lowman W; Hsueh PR; Paño-Pardo JR; Torre-Cisneros J; Souli M; Bonomo RA; Carmeli Y; Paterson DL; Pascual Á; Rodríguez-Baño J;
Clin Infect Dis; 2017 Oct; 65(10):1615-1623. PubMed ID: 29020250
[TBL] [Abstract][Full Text] [Related]
34. Carbapenem therapy is associated with improved survival compared with piperacillin-tazobactam for patients with extended-spectrum β-lactamase bacteremia.
Tamma PD; Han JH; Rock C; Harris AD; Lautenbach E; Hsu AJ; Avdic E; Cosgrove SE;
Clin Infect Dis; 2015 May; 60(9):1319-25. PubMed ID: 25586681
[TBL] [Abstract][Full Text] [Related]
35. Risk factors associated with preoperative fecal carriage of extended-spectrum β-lactamase-producing Enterobacteriaceae in liver transplant recipients.
Bert F; Larroque B; Dondero F; Durand F; Paugam-Burtz C; Belghiti J; Moreau R; Nicolas-Chanoine MH
Transpl Infect Dis; 2014 Feb; 16(1):84-9. PubMed ID: 24330161
[TBL] [Abstract][Full Text] [Related]
36. Comparison of therapy with β-lactam/β-lactamase inhibitor combinations or carbapenems for bacteraemia of nonurinary source caused by ESBL-producing Escherichia coli or Klebsiella pneumoniae.
Luo H; Xiao Y; Hang Y; Chen Y; Zhu H; Fang X; Cao X; Zou S; Hu X; Xiong J; Zhong Q; Hu L
Ann Clin Microbiol Antimicrob; 2021 Sep; 20(1):63. PubMed ID: 34488786
[TBL] [Abstract][Full Text] [Related]
37. Bloodstream infections due to extended-spectrum β-lactamase-producing Enterobacteriaceae among patients with malignancy: a systematic review and meta-analysis.
Alevizakos M; Gaitanidis A; Andreatos N; Arunachalam K; Flokas ME; Mylonakis E
Int J Antimicrob Agents; 2017 Nov; 50(5):657-663. PubMed ID: 28705665
[TBL] [Abstract][Full Text] [Related]
38. Risk factors for community-onset bloodstream infection with extended-spectrum β-lactamase-producing Enterobacteriaceae: national population-based case-control study.
Isendahl J; Giske CG; Tegmark Wisell K; Ternhag A; Nauclér P
Clin Microbiol Infect; 2019 Nov; 25(11):1408-1414. PubMed ID: 30986557
[TBL] [Abstract][Full Text] [Related]
39. Extended spectrum beta-lactamase producing Enterobacteriaceae causing bloodstream infections in rural Ghana, 2007-2012.
Eibach D; Belmar Campos C; Krumkamp R; Al-Emran HM; Dekker D; Boahen KG; Kreuels B; Adu-Sarkodie Y; Aepfelbacher M; Park SE; Panzner U; Marks F; May J
Int J Med Microbiol; 2016 Jun; 306(4):249-54. PubMed ID: 27222489
[TBL] [Abstract][Full Text] [Related]
40. Bacteremia due to extended-spectrum beta-lactamase-producing Enterobacteriaceae other than Escherichia coli and Klebsiella.
Huang SS; Lee MH; Leu HS
J Microbiol Immunol Infect; 2006 Dec; 39(6):496-502. PubMed ID: 17164953
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
